A human open-label phase I trial in SLE patients of Tocilizumab, a monoclonal antibody that inhibits binding of IL6 to its receptor, revealed improvements in disease activity and reduced levels of serum autoantibodies [59]. The gene discussed is IL6; the disease is systemic lupus erythematosus.